Moleculin CEO highlights Annamycin’s non-cardiotoxic profile in CEO Corner interview

Moleculin Biotech, Inc.

Moleculin Biotech, Inc.

MBRX

0.00
  • Moleculin management released a CEO Corner segment featuring CEO Walter Klemp highlighting Annamycin safety profile.
  • Klemp emphasized Annamycin was designed to avoid cardiotoxicity seen with traditional anthracyclines such as doxorubicin.
  • Segment positioned non-cardiotoxic profile as potential differentiator for relapsed or refractory AML patients, including those with prior anthracycline exposure or cardiac risk factors.
  • Klemp linked safety profile to potential regulatory and commercial advantages as Moleculin advances its pivotal Phase 3 MIRACLE trial of AnnAraC in relapsed or refractory AML.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604070836PRIMZONEFULLFEED9684739) on April 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.